Table 1.
Characteristics of 89 patients with grade 3 neuroendocrine neoplasms (G3 NEN) treated with etoposide-platinum (EP) chemotherapy.
| Baseline Characteristics | All (n = 89) |
|---|---|
| Age (years), median (IQR) | 61.6 (54.2–68.6) |
| Male gender, n (%) | 60 (67.4) |
| Hereditary syndrome, n (%) | 1 (1.1) |
| Current or previous tobacco use, n (%) | 49/71 (69) |
| Performance status, n (%) | |
| 0–1 | 61/78 (78.2) |
| ≥2 | 17/78 (21.7) |
| Primary NEN, n (%) | |
| Lung | 37 (41.6) |
| Pancreas | 27 (30.3) |
| Other digestive | 25 (28.1) |
| Functioning syndrome, n (%) | 1 (1.1) |
| Tumor stage, n (%) | |
| Localized or locally advanced | 18 (20.2) |
| Liver metastases | 61 (68.5) |
| Extra-hepatic metastases | 43 (48.3) |
| 2019 WHO classification, n (%) | |
| G3 NET | 10 (11.2) |
| LCNEC | 31 (34.8) |
| SCNEC | 48 (54.0) |
| Ki67 (%), median (IQR) * | 80.0 (57.5–90.0) |
| Biology, median (IQR) | |
| Albumin (g/L) ** | 32.0 (28.0–36.7) |
| Platelets (G/L) *** | 288.0 (210.2–381.8) |
| Hemoglobin (g/dl) *** | 11.9 (10.7–13.3) |
| Leukocytes (G/L) *** | 8.3 (6.3–10.8) |
| Alkaline phosphatase (UNL) *** | 1.3 (0.6–2.5) |
* 1 missing value, ** 16 missing values, *** 3 missing values. IQR, interquartile (25–75) range; LCNEC, large-cell neuroendocrine carcinoma; NEN, neuroendocrine neoplasm; NET, neuroendocrine tumor; SCNEC, small-cell neuroendocrine carcinoma.